---
authors: 
institution: 
project: 
tags:
  - MED
  - pathology
status: 
aliases: 
type: Pathology
date created: 09/21/2023, 10:30
date modified: 09/21/2023, 10:31
---

(Back to [[]])

# von Willebrand Disease

## Presentation
- **Mucocutaneous** bleeding
- **Hemarthroses** if VIII is low (3, 2N, sometimes 1)
## Etiology
- Deficiency or abnormality in [[von Willebrand factor]]
	- **Type 1**: deficiency in vWF
	- **Type 2**: abnormality in vWF
		- **2A**: abnormal function with decreased HMW multimers
		- **2B**: increased affinity of vWF to Gp1b and nonproductive agglutination
		- **2M**: abnormal function with normal HMW multimers
		- **2N**: decreased affinity for [[FVIII]]
	- **Type 3**: complete lack of vWF
## Diagnosis
### Type 1
- Pertinent negatives
	- Normal PT
	- Elevated PTT if FVIII deficient
- Low vWF
	- Normal or symmetrically decreased HMW multimers
- Coagulation dysfunction
	- Low FVIII sometimes
### Type 2
- Altered vWF multimers
	- **2A**: low vWF multimers
	- **2B**: 
	- **2M**: normal vWF multimers
	- **2N**: 
- Platelet dysfunction
	- **2A**: Adhesion defect
	- **2B**: Thrombocytopenia
	- **2M**: Adhesion defect
	- **2N**: 
- Coagulation dysfunction
	- **2A**: maybe VIII deficient; vWF activity:antigen < 0.7
	- **2B**: 
	- **2M**:  vWF activity:antigen < 0.7
	- **2N**: VIII deficient
### Type 3
- Pertinent negatives
	- Normal PT
	- Elevated PTT if FVIII deficient
- **Absent** vWF
- Coagulation dysfunction
	- Low FVIII
## Complications
- 
## Treatment
- **Exogenous vWF**: IV vWF concentrate
	- Works for all subtypes
- **Endogenous vWF**: DDAVP
	- Vasopressin analog; stimulates release
	- **Most effective against T1**
	- Less effective for T2A/M/N
	- **Contraindicated for T2B**
	- Ineffective for T3
	- Side effect: fluid retention
- **Antifibrinolytic therapy**
	- Aminocaproid acid
	- Tranexamic acid

---
